X

Trial Profile

A phase II, multi-centre, two-part study to evaluate the safety and efficacy of study drug [V 10153] in acute ischaemic stroke.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 14 Jan 2020

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Troplasminogen alfa (Primary)
Indications Embolism and thrombosis; Stroke
Focus Adverse reactions; Therapeutic Use
Acronyms VASST
Sponsors Vernalis

Most Recent Events

09 Dec 2015 Treatment arms changed from 1 to 5, Study design changed to Non-randomized as reported by ClinicalTrials.gov.
24 Mar 2009 Patient numbers amended from 80 to 49 as reported by ClinicalTrials.gov.
24 Mar 2009 End date added from ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com